LLY: FY25 Deep Dive
FY25 crossed $65B revenue on the incretin cycle. Mounjaro $23.0B and Zepbound $13.5B together are 56% of the company. Free cash flow $9.0B on $7.8B capex — the manufacturing build-out is the governing capital story.
Key Takeaways
Eli Lilly closed fiscal 2025 (calendar year ended December 31, 2025) at $65.2 billion of revenue, a roughly 45% year-over-year expansion that makes Lilly the fastest-growing US mega-cap in absolute dollars. The incretin franchise dominates: Mounjaro (tirzepatide for Type 2 diabetes) reached $23.0 billion full-year sales, Zepbound (tirzepatide for obesity) reached $13.5 billion, and combined these two drugs now generate 56% of company revenue — an unprecedented single-molecule concentration at mega-cap scale. Free cash flow came in at $9.0 billion on operating cash flow of $16.8 billion and $7.8 billion of capital expenditures directed toward manufacturing capacity expansion. The company returned $9.5 billion to shareholders — $5.4 billion in dividends plus $4.1 billion in buybacks — against a $15 billion total repurchase authorization. Sell-side coverage is 10 analysts with 9 Buy ratings and one notable bear: HSBC (Rajesh Kumar) downgraded from Hold to Reduce on March 17 with an $850 price target, the consensus low. Three April price-target raises (Guggenheim, Morgan Stanley, BofA) bracketed the consensus at $1,232, high $1,350.
Main business structure
Lilly reports a single pharmaceutical segment, disaggregated by product franchise. FY25 revenue breakdown (key products):
| Product | Therapy Area | FY25 Revenue ($M) | % of Total |
|---|---|---|---|
| Mounjaro | Type 2 diabetes (tirzepatide) | 22,965 | 35.2% |
| Zepbound | Obesity (tirzepatide) | 13,542 | 20.8% |
| Other Incretin (Trulicity etc.) | Diabetes | ~3,500 | ~5% |
| Verzenio | Oncology (breast cancer) | ~5,500 | ~8% |
| Jardiance | Diabetes (SGLT2, co-promoted with BI) | ~3,200 | ~5% |
| Taltz | Immunology (IL-17) | ~3,200 | ~5% |
| Other products | Mixed | ~13,300 | ~20% |
| Total | 65,179 | 100% |
Figures for non-Mounjaro / non-Zepbound products are approximate roll-ups of multiple disclosed lines — the exact sub-line splits appear in the 10-K product revenue tables.
The tirzepatide franchise (Mounjaro + Zepbound combined = $36.5 billion) is the single most material product cluster in US pharma history. The prior benchmark for single-molecule concentration at mega-cap scale was Humira (AbbVie) at its peak — that was one molecule at $21 billion peak annual sales. Tirzepatide in FY25 is already 75% larger than Humira's all-time peak.
Geographic mix. US accounts for approximately 65-70% of revenue. International is roughly 30-35%, dominated by Europe and Japan with smaller contributions from emerging markets. Incretin demand is supply-constrained — FY25 international expansion was throttled by manufacturing capacity rather than demand.
Customer concentration. Three major wholesalers (McKesson, Cardinal Health, Cencora) collectively process the majority of US pharmaceutical sales; each individually crosses the 10% disclosure threshold per the 10-K. This is the standard structural feature of US branded pharma, not a Lilly-specific concentration risk.
Scale anchors. Manufacturing capacity expansion: FY25 saw completion of the Concord, NC and Research Triangle Park injectable production facilities, with additional capacity under construction in Indiana, Ireland, and Germany. R&D spend is typically 25% of revenue ($16 billion in FY25 at that run-rate). Pipeline hit in April 2026 was the orforglipron ATTAIN-1 Phase 3 readout at 13.8% mean weight loss, landing in the middle of analyst efficacy windows. Retatrutide (next-generation triple-agonist) Phase 3 trials remain in progress.
Key core metrics (3-year trend)
1. Total revenue growth (FY22-FY25)
| FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|
| Total revenue ($B) | 28.5 | 34.1 | 45.0 | 65.2 |
| YoY | +1% | +20% | +32% | +45% |
Revenue growth accelerated each year of the incretin cycle — FY25's $20B incremental was the largest single-year dollar expansion in company history.
2. Tirzepatide franchise (Mounjaro + Zepbound combined)
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Combined revenue ($B) | 5.2 | 16.4 | 36.5 |
| YoY | — | +216% | +123% |
Combined tirzepatide went from $5B to $36.5B in two years. Mounjaro launched 2022, Zepbound launched November 2023. FY25 is the second full year of Zepbound commercialization.
3. Free cash flow
| FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|
| OCF ($B) | 7.6 | 4.2 | 8.8 | 16.8 |
| Capex ($B) | 2.4 | 5.4 | 7.5 | 7.8 |
| FCF ($B) | 5.2 | (1.2) | 1.3 | 9.0 |
FCF inflected from negative in FY23 (manufacturing investment cycle) to $9 billion in FY25 as the revenue ramp caught up with the capex build. FCF margin remains below peer pharma (9% of revenue vs 25-30%+ at Big Pharma peers) because the supply-constrained incretin cycle is still requiring incremental capacity investment; the FCF normalization to peer levels is a 2-3 year process assuming incretin growth moderates.
4. Capital return trajectory
| FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|
| Dividends ($B) | 3.7 | 4.2 | 4.8 | 5.4 |
| Buybacks ($B) | 1.5 | 0 | 0 | 4.1 |
| Total return ($B) | 5.2 | 4.2 | 4.8 | 9.5 |
Buybacks restarted in FY25 after two years of suspension (manufacturing capex priority); $10.9 billion remains under the $15 billion authorization. Dividend has grown ~15% CAGR over the trailing 3 years.
Market evaluation
Sell-side coverage (as of late April 2026). 10 analysts cover the stock — a narrower coverage list than most mega-caps.
| Rating | Count |
|---|---|
| Buy | 9 |
| Hold | 0 |
| Sell (incl. Reduce) | 1 |
Price targets. Consensus $1,232.40, range $850 (low: HSBC) to $1,350 (high: likely Morgan Stanley at $1,327).
Recent analyst activity (Feb 25 through April 24, 2026). Five covered events:
- RBC Capital (Trung Huynh) initiated Outperform at $1,250 on February 25
- HSBC (Rajesh Kumar) downgraded Hold → Reduce on March 17 with PT $1,070 → $850 — the only rating change in the window and the consensus low. Kumar's thesis: incretin competition from oral formulations (orforglipron launch timing, AMGN's MariTide) will compress pricing more than Street models assume.
- BofA (Jason Gerberry) raised PT $1,293 → $1,294 on April 2 (Buy maintained)
- Morgan Stanley (Terence Flynn) raised PT $1,313 → $1,327 on April 10 (OW maintained)
- Guggenheim (Seamus Fernandez) raised PT $1,163 → $1,183 on April 22 (Buy maintained)
The HSBC bear and the consensus bulls frame the core debate: both agree on the near-term incretin revenue trajectory; they disagree on the sustainability of incretin pricing as oral formulations enter the market and MariTide (AMGN) Phase 3 data continues to mature.
Buy-side positioning. LLY is a core healthcare mega-cap holding with significant AI-era "obesity thesis" momentum. Short interest typically below 1% of float. Positioning is not extreme at either end.
FY25 corporate structure: the incretin concentration risk, made literal
FY25 makes one structural feature impossible to ignore: a single molecule (tirzepatide) now generates 56% of Lilly revenue, and the two brands selling it (Mounjaro + Zepbound) together are $36.5 billion — larger than any single-molecule franchise in US pharma history. The consequence is that the FY26-FY28 Lilly model is fundamentally a tirzepatide model: if tirzepatide pricing holds and supply-constrained demand continues to convert to revenue, the company executes; if oral-GLP-1 competitors (orforglipron itself is a Lilly product, but second-generation entrants like AMGN's MariTide target the same end market) compress the pricing, the concentration cuts the other way. The April 15, 2026 orforglipron ATTAIN-1 Phase 3 readout at 13.8% mean weight loss was a material de-risking event — within the middle of efficacy modeling ranges, not a blow-out beat — which the Street interpreted as validating the oral-GLP-1 category without reshuffling market leadership. The HSBC Reduce thesis bets against that interpretation; the consensus Buys accept it. This is the single most material model debate in pharma mega-cap coverage.